{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:26:44Z","timestamp":1780396004829,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Pharmaceuticals Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jcf.2023.11.012","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T09:52:41Z","timestamp":1707904361000},"page":"499-505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Inhaled antimicrobial prescribing for Pseudomonas aeruginosa infections in Europe"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7799-132X","authenticated-orcid":false,"given":"Callum M.","family":"Sloan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Sherrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1353-950X","authenticated-orcid":false,"given":"Gisli G.","family":"Einarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven J.","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2222-4238","authenticated-orcid":false,"given":"Silke van","family":"Koningsbruggen-Rietschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1705-4780","authenticated-orcid":false,"given":"Nicholas J.","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6471-549X","authenticated-orcid":false,"given":"Damian G.","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.11.012_bib0001","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2023.11.012_bib0002","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.11.012_bib0003","unstructured":"Zolin A., Orenti A., Jung A., van Rens J., et al. ECFSPR Annual Report 2021. 2023."},{"key":"10.1016\/j.jcf.2023.11.012_bib0004","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.012_bib0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2217\/fmb-2021-0150","article-title":"Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis","volume":"16","author":"Elborn","year":"2021","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jcf.2023.11.012_bib0006","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jcf.2020.05.011","article-title":"Building global development strategies for CF therapeutics during a transitional CFTR modulator era","volume":"19","author":"Mayer-Hamblett","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.012_bib0007","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40506-018-0157-9","article-title":"Antimicrobial stewardship in the treatment of infections among patients with cystic fibrosis","volume":"10","author":"Bhowmick","year":"2018","journal-title":"Curr Treat Options Infect Dis"},{"key":"10.1016\/j.jcf.2023.11.012_bib0008","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.012_bib0009","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcf.2019.01.008","article-title":"Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: a systematic review","volume":"18","author":"Somayaji","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.012_bib0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jcf.2009.03.001","article-title":"Implementation of European standards of care for cystic fibrosis\u2013control and treatment of infection","volume":"8","author":"Elborn","year":"2009","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.012_bib0011","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jcf.2019.10.006","article-title":"Antimicrobial resistance in cystic fibrosis: a Delphi approach to defining best practices","volume":"19","author":"Zemanick","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.012_bib0012","article-title":"Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis","volume":"11","author":"Smith","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2023.11.012_bib0013","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1186\/s12913-021-07196-4","article-title":"Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review","volume":"21","author":"Medlinskiene","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jcf.2023.11.012_bib0014","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","volume":"4","author":"Langton Hewer","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jcf.2023.11.012_bib0015","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/antibiotics10030338","article-title":"Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives","volume":"10","author":"Taccetti","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.jcf.2023.11.012_bib0016","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2213-2600(20)30331-3","article-title":"Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial","volume":"8","author":"Hewer","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2023.11.012_bib0017","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jcf.2019.07.008","article-title":"The impact of CFTR modulator therapies on CF airway microbiology","volume":"19","author":"Rogers","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.012_bib0018","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcf.2019.10.025","article-title":"Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials","volume":"19","author":"Davies","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.012_bib0019","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2023.11.012_bib0020","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1513\/AnnalsATS.201812-863OT","article-title":"Developing inhaled antibiotics in cystic fibrosis: current challenges and opportunities","volume":"16","author":"Nichols","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2023.11.012_bib0021","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09031936.00018414","article-title":"Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review","volume":"44","author":"Brodt","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2023.11.012_bib0022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.arbres.2021.03.009","article-title":"Effectiveness and safety of inhaled antibiotics in patients with chronic obstructive pulmonary disease. A multicentre observational study","volume":"58","author":"De la Rosa Carrillo","year":"2022","journal-title":"Arch Bronconeumol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323016831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323016831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:32:51Z","timestamp":1777649571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323016831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1569199323016831"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.11.012","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled antimicrobial prescribing for Pseudomonas aeruginosa infections in Europe","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}